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The developmental neurotoxicity of phenytoin, isotretinoin, and methamphetamine has been reviewed to illustrate effects from both therapeutic
and illicit drugs to which people are exposed and which either induce or show the potential for inducing learning disabilities following in utero expo-
sure. In each case both human and experimental animal data are presented and compared where possible. The findings point to several conclu-
sions. First, some drugs in current use induce developmental neurotoxicity, and it cannot safely be assumed that there are not more as yet
unidentified. Second, of the types of neurotoxicity induced by drugs, learning disabilities figure prominently. Third, the effects observed are depen-
dent on both the drug's mechanism of action and the period of brain development during which exposure occurs. Fourth, with the exception of CNS
teratogens, it is not yet possible to predict which periods of brain development are the most vulnerable for the induction of learning disabilities, as
seen by the different patterns of critical periods for phenytoin and isotretinoin compared to methamphetamine. Fifth, as seen with isotretinoin, exist-
ing drugs that cause developmental neurotoxicity are not the only problem; new drugs with such effects are still being introduced. Sixth, only a
small fraction of the drugs currently in use have ever been examined for developmental neurotoxicity; hence, the full scope of the problem cannot
even be accurately estimated based on current information. It is concluded that prevention of new cases caused by drugs such as isotretinoin
should be a high priority for future regulatory action. - Environ Health Perspect 102(Suppl 2):145-153 (1994).
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Introduction
The purpose of this paper, as the title
implies, is to review evidence that there are
established examples of both therapeutic
and illicit drugs that induce prenatal neu-
rotoxicity. While suspicions about such
effects have been gathering for many years,
a more complete link between specific
drugs and developmental neurotoxicity
which extends from experimental animals
to humans has only emerged in the last 15
years.
Rather than present a list of all the
drugs proven or suspected of inducing
developmental neurotoxicity, I have
selected three examples that illustrate what
I believe to be the most common pattern
by which this kind of finding is revealed.
The pattern begins with clinical case
reports, in which a small number of cases
are identified, and the suggestion is made
that the effects seen in the affected chil-
dren are related to a particular intrauter-
ine drug exposure. Next, experimental
animal research tests this hypothesis. In
the cases presented below, such data
showed a direct cause-effect relationship
in animals between the drug in question
and various neurological and behavioral
abnormalities in the offspring. The animal
data also usually establish dose-effect and
exposure-effect relationships, provide con-
trol over potential confounding factors
such as undernutrition and changes in
postnatal rearing environment, identify
sites of brain injury, and ultimately,
uncover mechanisms of drug action.
Following the studies in experimental ani-
mals, the final phase is the conduct ofepi-
demiologic studies in humans. These are
usually prospective and are controlled by
matching comparison subjects to cases
and by using statistical methods ofadjust-
ment for covariates known or suspected to
be confounders. Epidemiologic studies are
not necessarily triggered by the animal
experimental studies, but they neverthe-
less constitute the culmination of a
process that when positive, implicates the
drug in question to adverse effects. This,
of course, is an idealized three-step
process, and it seldom runs true to course.
Nevertheless, it fits sufficiently well to use
it to provide structure to this review.
The three drugs I have selected for
review are the anticonvulsant phenytoin
(Dilantin), the antiacne drug isotretinoin
(Accutane), and, for the illicit drug exam-
ple, the centrally acting stimulant
methamphetamine (street names rock, ice,
meth, or speed).
The Drugs and Their Actions
Phenytoi
Phenytoin is associated with the fetal
hydantoin syndrome (FHS). FHS was first
described by Hanson and Smith in 1975
(1). This was not the first time an anticon-
vulsant drug had been linked to develop-
mental toxicity, that had first been
suggested by Meadow (2), who suggested a
link between anticonvulsants, including
phenytoin, and certain congenital malfor-
mations. However, Hanson and Smith (1)
were the first to suggest a syndrome associ-
ated with hydantoin exposure and the first
to suggest that an integral part of the syn-
drome was a neurotoxic effect. The features
Hanson and Smith (1) described for FHS
involve the CNS including developmental
delay and mild mental subnormality; cran-
iofacial structures, including midfacial
hypoplasia, hypertelorism, flattened
philtrum, and shortened nose; growth
effects, in this case growth retardation; and
limb development, including distal pha-
langeal hypoplasia and small nails.
It is important to note that FHS did
not occur in isolation. The fetal alcohol
syndrome had been described just 2 years
earlier by the same group, and in 1975 this
group also described a fetal trimethadione
syndrome (3). Actually, their paper was
predated by a paper by Hill et al. (4),
although the effects described by Hill et al.
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Figure 1. Mean (± SEM) early locomotor activity counts on each day and summed across test days (inset). *p<0.05;
**p<0.01. FromVorhees and Minck(9).
were not characterized as a syndrome per
se. Shortly thereafter, a possible fetal barbi-
turate syndrome was described (5).
Subsequent reports were to describe a fetal
primidone syndrome (6), a fetal valproate
syndrome (7), and most recently a fetal
carbamazepine syndrome (8).
Following the initial case reports of
FHS, a series ofexperimental animal inves-
tigations were published. These may gener-
ally be categorized as of two types. First
were those attempting to link phenytoin to
congenital malformations. I will not review
those here. Second were those attempting
to link phenytoin to developmental neuro-
toxicity; I will highlight some ofthese.
The investigators in this area
approached the issue of possible develop-
mental neurotoxic effects from a perspec-
tive oftrying to eliminate the concomitant
influence of malformations on the exposed
progeny. This was done to more clearly
determine if there were CNS effects of
intrauterine phenytoin exposure that were
separate and distinct from those attribut-
able to dysmorphogenesis of major organ
systems. Therefore, these experiments
administered phenytoin at subteratogenic
doses.
Only those neurotoxic effects seen in
the offspring of phenytoin treated dams
that have been replicated numerous times
will be presented here. During early post-
natal development, rats exposed to pheny-
toin in utero exhibit heightened locomotor
movement, primarily pivoting. This is
illustrated in Figure 1 and is taken from
Vorhees and Minck (9). The pattern is
always consistent. The progeny appear nor-
mal on day 7, but become more active than
controls on day 9 and subsequent days. As
the progeny grow older, their hyperactivity
becomes more pronounced. Figure 2 illus-
trates this for the same progeny as shown
earlier in life in Figure 1. The apparatus is
a figure-eight-shaped activity monitor; but
the effect appears equally clearly in circular
and square open-fields, and in hold-board
chambers. Note in the right of Figure 2
that accompanying the hyperlocomotion of
the phenytoin-exposed offspring is a
reduced rearing frequency. Animals that
ambulate more, rear less. Perhaps this
inverse relationship is a function of com-
peting responses, such that rearing is
crowded out ofthe animal's response reper-
toire by the press to ambulate. However,
an alternative explanation is that these rats
rear less because they are unstable. We later
found that phenytoin-exposed animals
have balance and righting reflex abnormali-
ties that lend credence to the latter inter-
pretation (below).
As evidence that phenytoin offspring
have balance abnormalities, Elmazar and
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Sullivan (10) reported that rats exposed
prenatally to this drug show large delays in
the normal developmental acquisition of
the air-righting reflex. In rats, this reflex
develops rapidly during the second week of
postnatal life and once attained gains addi-
tional speed during the third week of life.
We have replicated Elmazar and Sullivan's
(10) air-righting effects in rats prenatally
exposed to phenytoin in several experi-
ments, one ofwhich is illustrated in Figure
3 (11). As can be seen, regardless of the
scoring criterion used, phenytoin offspring
were not only delayed in the acquisition of
the air-righting reflex, they never attained
the speed ofresponse seen in controls. The
data in Figure 3 also include groups
exposed to two other hydantoin anticon-
vulsants and to the inactive hydantoin core
molecule itself. These other hydantoins
produced no delays resembling those seen
the phenytoin group. This illustrates an
important point: it is risky to rely too heav-
ily upon structure-activity relationships in
making predictions about which drugs are
capable of inducing developmental neuro-
toxicity and which ones are not.
One ofthe most striking effects ofpre-
natal phenytoin is that when the offspring
reach 40 to 50 days, a percentage begin to
exhibit a neurological abnormality. This
takes the form of exessive circling move-
ments. It is different from the kind of cir-
cling seen in normal animals because of its
speed and repetitive nature. However, it is
not seen ifthe animal is placed in an open
arena. It is most conspicuous in confined
spaces where the walls are close to the ani-
mal, such as when the animal is first
returned to its home cage, and in the nar-
row channels of a maze. Under these cir-
cumstances, the affected individuals will
episodically exhibit bouts of circling in
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Figure 2. Mean (± SEM) locomotor activity counts on each day of testing in the figure-eight activity monitor (left) and
rearing counts underthe central canopyaveraged acrosstestdays(right). **p<0.01. FromVorhees and Minck(9).
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Figure 3. Mean proportion of animals in each group successfully righting themselves by the 2/3 (left) and the 3/3 (right)
trial criterion based on visual scoring of righting by two observers. *p<0.05; *pO 01. From Minck et al. (11); reprinted
with permission.
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Figure 4. Mean (± SEM) startle amplitude (left two panels) and latency to peak response (right panel) avera
50trials(25acoustic and 25tactile stimulustrialtypes). **p<0.l1. FromVorheesand Minck(9).
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Figure 5. Mean (± SEM) latency(sec) to find the goal in the Morris hidden platform maze in phenytoin and
spring under place test conditions. Extinction refers to time spent in the goal quadrant. Shift refers to reloc
goal totheoppositequadrant.+p<O.10; *p<0.05. FromVorheesand Minck(9).
iged across
which theywill turn several times in a row.
As they turn they often tilt their head in
the direction ofthe turn with the inside ear
lower than the outside one. However, we
have been careful to rule out middle ear
infection as a possible cause of this symp-
tom.
Prenatal phenytoin exposure also affects
another complex reflex, the startle
response. An example ofphenytoin's effects
on startle is shown in Figure 4 (9).
Phenytoin-exposed offspring show a reli-
able reduction in startle amplitude to either
an acoustic or tactile stimulus as adults (as
reflected in their maximum, Vmax, and
average responses), but no change in the
latency to their maximum response(Tnm).
One ofthe most striking effects ofpre-
natal phenytoin exposure is its effects on
offspring learning. We have relied upon
two well-established tests of learning: The
Morris hidden platform maze and a com-
plex multiple-T water maze, termed the
Cincinnati maze. These tests were chosen
because existing evidence suggests that they
measure different (although perhaps some-
what overlapping) aspects oflearning. The
Morris maze is a test ofspatial navigation,
which relies upon the use of distal cues
(12). This test is known to be sensitive to
hippocampal damage (13). The complex
multiple-T water maze is a test ofwhat is
termed "dead-reckoning" navigation,
which relies upon the use ofproximal cues
and vector estimation (14). The brain
region to which this test is sensitive is not
as well-established as it is for the Morris
maze, but current evidence suggests that
cortical lesions and probably frontal cortex
is the zone that has the greatest effect on
complex maze problem solving following
lesion induction (15).
The effects ofprenatal phenytoin expo-
sure on Morris maze learning are shown in
Dd Figure 5 (9). As can be seen, the pheny-
toin-exposed animals took significantly
longer to navigate to the hidden platform
than controls.
As clear as the effect on Morris-maze
acquisition is, the effect ofprenatal pheny-
toin exposure on the Cincinnati water
maze is even greater. An example is shown
in Figure 6 (11). As can be seen, all pheny-
toin-exposed offspring make many more
errors than controls. Another aspect evi-
dent in Figure 6 is that there are two dis-
tinct subgroups of phenytoin-exposed
24 offspring. Those that exhibit abnormal cir-
cling behavior are the most severely
control off- affected (Figure 6,group PHT-C ) and
,ation ofthe show little improvement in performance
across trials. By contrast, those phenytoin-
Volume 102, Supplement2, June 1994
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Figure 6. Mean 1±SEM) number of errors committed on each trial in the Cincinnati water maze (path B). **p<0.0 from
control. PHI-C, phenytoin-exposed animals exhibiting circling; PHI-NC, phenytoin-exposed animals not exhibiting cir-
cling; MPH, mephenytoin-exposed group; ETH, ethotonin-exposedgroup; HYD, hydantoin-exposed group: CON, control
group.
exposed offspring that do not exhibit
abnormal circling (Figure 6, group PHT-
NC) show impaired learning, but they
eventually succeed in learning the maze;
the difference is that the latter animals
learn at a slower rate than controls or ani-
mals exposed to other hydantoins.
To bring things full circle, consider the
recent prospective study by VanOverloop
et al. (16) of children exposed prenatally
to phenytoin alone or in combination with
one of several other anticonvulsants. They
report that such children exhibit significant
reductions in full-scale IQ, reduced scores
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on the Visual Motor Integration test, and
reduced counts on a measure oflocomotor
activity when the children were assessed at
between 4 to 8 years of age compared to
controls. Controls were children identified
at the same time in the study's prospective
enrollment process and were selected
because they were born in one ofthe target
hospitals with three or more minor con-
genital anomalies. On the verbal portion of
the Wechsler tests of intelligence (WPPSI
or WISC-R, depending on their age), the
most affected subscales among the pheny-
toin-exposed children were those for
_ ISOTRETINOIN
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Rgure7. Mean performance onthe Stanford-Binet IVtestof5-year-old children exposed to isotretinoin in uteroand
trols. FromAdamsand Lammer(19); reprinted with permission.
Similarities and Comprehension. However,
the most striking differences occurred on
the performance subscales. Three perfor-
mance subscales showed significant reduc-
tions in the phenytoin-exposed children:
Block Design, Mazes, and Animal House
Retreat. In terms of the size of the differ-
ences, the largest effect by far was on
mazes, and this would appear to be the task
most analogous to the animal data showing
severely impaired complex maze learning.
VanOverloop et al. (16) also found a
number of other differences that were
nearly statistically significant. Overall, their
data suggest that while phenytoin-exposed
children may not be at risk for mental
retardation, they may be at risk for specific
learning disabilities. Since approximately
0.5% of the population has epilepsy, and
over 95% ofepileptics are treated for their
disorder with medication and phenytoin is
the most widely prescribed of these med-
ications, it stands to reason that thousands
of exposed infants are born in the United
States per year with the potential ofpheny-
toin-induced learning disorders. If even
10% ofthose exposed prenatally to pheny-
toin are learning disabled, then this one
anticonvulsant alone is inducing more than
a thousand learning disabilities per year in
the United States and thousands more in
the rest of the world. While this is small
from a national perspective, disabilities
such as these are not only a lifelong strug-
gle for those affected and their families,
they also carry a lifetime financial burden
to society. If these could be prevented by
policies designed to avoid certain anticon-
vulsants during pregnancy, the benefits
would be substantial.
Retinoids
The next example comes from the
retinoids, of which vitamin A (retinol) is
the most familiar. Retinol's teratogenicity
in animals has been recognized since the
early 1950s, but its developmental neuro-
toxicity was not demonstrated experimen-
tally until the 1970s.
In the 1980s Hoffmann-LaRoche
developed a congener ofretinoic acid (RA),
13-cis-retinoic acid. This compound exhib-
ited a high degree of therapeutic efficacy
for severe cystic acne, a disorder for which
highly efficacious alternative treatments are
not available. The company's own preclini-
cal animal experiments demonstrated that
13-cis-RA (isotretinoin, Accutane) was ter-
atogenic. However, the company con-
ducted no developmental neurotoxicity
con- testing because it was not required by the
US Food and DrugAdministration (FDA).
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Figure 8. Number ofcases with malformations by IQ range and showing the relationship between major malformations
and general mental ability in 5-year-old children exposed to isotretinoin in uteroand controls. From Adams and Lammer
(191; reprinted with permission.
Accordingly, the company sought FDA
approval as a category X drug (contraindi-
cated during pregnancy). The drug was
approved in September 1982. Because of
the nature ofthe laws in the United States,
once the drug was on the market it could
be prescribed by any physician for any pur-
pose, not just for those purposes for which
it was originally indicated. Furthermore,
under current US law, the FDA has no
legal authority to restrict is use. This drug,
however, was not only highly efficacious
for cystic acne, it was also effective for
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acne, and by 1985 an estimated 160,000
women of childbearing age had taken the
drug. Since nowhere near this number of
women has cystic acne, the obvious had
happened: physicians were over-prescribing
the drug. It did not take long for
isotretinoin-associated malformation cases
to begin to appear. In 1985, Lammer et al.
(17) collected all the known retrospectively
ascertained cases plus a cohort of prospec-
tively ascertained cases. In both groups he
demonstrated unequivocally a human mal-
formation syndrome caused by
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Figure 9. Mean (± SEM) peak startle amplitude (left panel), average amplitude (center), and latency to peak response
(right) averaged across 50 acoustic startle trials. 'p<0.10; *p<0.05; **p<0.01. MA, prenatal methamphetamine-treated
group; Con, controls.
isotretinoin. The affected children showed
craniofacial, cardiac, thymic, and CNS
malformations in those born, and increased
malformations among those that never
reached term. Even without these data, it
was possible to predict that isotretinoin
would also be a developmental neurotoxin
(18). Indeed, the company could have pre-
dicted this had it attended to the scientific
literature. The prediction could be based
on the substantial series of already pub-
lished animal experiments. I have summa-
rized these in Table 1.
Animals exposed to retinoids during
organogenesis exhibit a variety of dysfunc-
tions in the absence of malformations, but
the most reliably reported effect was a
deficit in complex maze learning. Given
this, it was a somber but compellingly
straightforward prediction that iso-
tretinoin-exposed children would be men-
tally retarded or learning disabled and
further, that such effects would be seen not
only among those malformed, but also
among exposed children who were other-
wise completely normal in appearance
(18). Regrettably, this scientific prediction
proved to be only too correct. Recently,
Adams and Lammer (19) have completed a
neuropsychological evaluation of 31
prospectively ascertained cases and a similar
number of matched controls. The psycho-
metric findings are summarized in Figure
7. As can be seen, the exposed children
show a striking downward shift in their IQ
distribution on the Stanford-Binet IV test
of intelligence. Figure 8 shows only the
isotretinoin-exposed children's IQ data
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Figure 10. Mean (± SEM) maximum amplitude of the
acoustic startle response averaged across test ages and
trials forfemales. *p<0.05; **p<0.01 compared to control.
From Vorhees etal. (26,27).
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Table 1. Summary of retinoid-induced behavioral dysfunctions in rats following prenatal exposure
Exposure period,
Reference Agent Strain days Function
Malakhovskii (28,29) Retinyl ester Albino 9 Activity
Butcher et al. (30)
Hutchings et al. (31)
Hutchings and Gaston(32)
Vorhees(33)
Coyle and Singer(34)
Vorhees et al. (35)
Vorhees et al. (36)
Mooney et al. (37)
Adams (38)
Nolen (391
Saillenfait and Vannier(40)
Retinyl acetate
Retinol
Retinol
Retinyl palmitate
Retinyl palmitate
Wstar
Wistar
F344
Wistar
Retinyl palmitate SD
Retinyl palmitate SD
Retinyl palmitate SD
Retinyl palmitate SD
trans-Retinoic acid SD
Retinyl palmitate SD
8-10
8-10
8-10
5-7,8-10,11-13,14-16,17-19
7-20
7-9b
8-10
8-10,11-13,14-16
6-20
Effect
Agress~ion
Active avoidance
Biel maze
5+/5- Operant learning
5+/5 Operant learning
Y-Maze learning
Biel maze
Henderson puzzle box
T-Maze learning
Activity
Biel maze
Cliff avoidance
Surface righting
Negative geotaxis
Swimming ontogeny
Pivoting
Earlyactivity
Spontaneous alternation
Biel maze
Active avoidance
Passive avoidance
Rotorod
Head elevation
Shoulder elevation
Hindleg elevation
Air righting
Crawling
Head pointing
Cliff avoidance
Rearing
Wire climbing
Walking
Negative geotaxis
Pivoting
Surface righting
Eye opening
Hair emergence
Negative geotaxis
Ultrasound
Negative geotaxis
Auditory startle
Open field activity
M-maze
Running wheel
Active avoidance
Surface righting
Swimming ontogeny
Pupil constriction
Auditory startle
Negative geotaxis
Open field activity
Rotorod
T Errors
4~Acquisition
S1-5 Extinction
4~Responding
1-Avoidance
T Errors
TITime
IlTime 11-13
T18-10
I Errors 8-10,11-13
Delayed
Delayed
Delayed
Delayed
T Rearing
IErrors
T Avoidance
4~Performance
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
Delayed
I Vocalization
Delayed
Delayed
I
I Latency
I
Delayed
Delayed
Delayed
I-
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Table 1 Continued.
Reference Agent Strain
Exposure period,
days Function
24-hractivity
M-maze
Effect
Nl Nocturnal
Retinyl acetate SD Pinna detachment
Eye opening
Incisoreruption
Surface righting
Cliffavoidance
Graspholding
Negative geotaxis
Swimming ontogeny
Omen field activity
S /S operant learning
aSD =Sprague-Dawley. bDating method correctfrom authors' original date sothatall pregnancies are uniformlydated as evidence ofconception is setequal today zero ofgestation.
coded for malformation type. Two obser-
vations stand out from these data: First,
those children with severe CNS malforma-
tions are the ones with the most severe
mental retardation. This confirms one of
the basic principles of developmental neu-
rotoxicity developed from animal experi-
ments, that CNS teratogens (i.e., agents
that induce gross malformations of the
brain) are reliably developmental neurotox-
ins at lower doses (doses that do not cause
neural tube defects) (20). The second
observation is that some children with
moderate or milder degrees of IQ reduc-
tion had no malformations whatsoever.
This reveals the principle that one cannot
predict developmental neurotoxicity based
on the presence or absence of malforma-
tions alone (21).
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This brings the case of isotretinoin full
circle. It began with human collected case
reports and a small prospective cohort in
which isotretinoin's embryopathic effects
were described, then the drug's develop-
mental neurotoxicity was predicted based
on already extant animal data, and finally
its developmental neurotoxicity was proven
in a human prospective study. The latter
data represent, beyond any doubt, the most
clear-cut human developmental neurotoxi-
city data ever obtained.
Metnampnetamine
Methamphetamine (MA) is the N-methy-
lated congener of amphetamine. Its phar-
macology is the same as that of
amphetamine except that MA is two to
three times more potent as a CNS stimu-
lant. Amphetamines have been abused for
their neurostimulant effects for many years,
but following the emergence of the free
base use pattern ofcocaine, it was not long
before users discovered that MA could also
be smoked, if it was sufficiently pure. The
smoking of MA has led to a resurgence of
illicit use of this drug and along with it, a
concern for infants born to women using
MA.
Several studies have appeared on the
possible effects of MA on infants following
intrauterine exposure. Three of these are
worth noting. In the first, Oro and Dixon
(22) described a group of infants born to
women using MA, cocaine, or both. Oro
and Dixon found that the stimulant group
showed intrauterine growth retardation
and altered neonatal behavior. The latter
included lethargy, poor feeding, tremors,
and abnormal sleep, among others, com-
ommitted in pared to a narcotic-exposed group or a
ross trials. non-drug-exposed control group. Sub-
al.(26,2). sequently, Dixon and Bejar (23) reported
an increased incidence of intraventricular
hemorrhages, echodensities, and cavitations
seen on cranial ultrasonographs of stimu-
lant exposed infants. About one-third of
the infants were exposed to MA and the
remainder were exposed to cocaine or
cocaine and narcotics. The abnormal sono-
grams were found in all stimulant-exposed
groups compared to the comparison group.
There were no differences in abnormal
sonogram findings between infants exposed
to MA and those exposed to cocaine.
=Control
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36- MA 11-20 *
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24
ACQ TEST RE-ACQ SHIFT
Figure 12. Mean(±f)
time (sec) to find the hidden platform
drneahphase of testing in the Morris navigation test.
Acq: acquisition phase, consisting of 24 trials (8
trials/day); test: memory phase, consisting of 4 trials with
the platform removed (for this measure the ordinate rep-
resents the time spent in the goal quadrant); re-acq: rein-
statement phase, consisting of 4 trials with the platform
in its original location; shift: new learning phase, consist-
ing of 8 trials with the platform moved to a location in the
opposite quadrant of the tank. *p<0.D5; **p<0.01 com-
pared to controls. From Vorhees et al. (26,27).
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In between the two reports by Dixon
(22,23) and Little et al. (24) reported on
52 women and their infants exposed to
MA. Little et al. reported that these infants
were intrauterinely growth retarded, but
that no increase in birth defects occurred.
They conducted no behavioral testing.
Unlike the situation with isotretinoin,
the animal data available on prenatal MA
were not adequate for making predictions
of human developmental neurotoxicity.
Therefore, we sought to improve the situa-
tion by developing a high-dose early expo-
sure model. This was at variance with the
existing published data, which were
entirely devoted to a constricted portion of
the dose-response range, i.e., low doses.
In one experiment dl-MA (50 mg/kg,
twice a day) was administered to rats on
days E7 to E12 ofembryonic development.
The offspring exhibited reduced olfactory
orientation to their home-cage scent,
reduced pivoting locomotion early in life,
and heightened acoustic-tactile startle reac-
tivity as weanlings. The latter may be seen
in Figure 9 (25). However, when these
same offspring were tested on a complex
water maze, they showed no learning
deficits. By comparison, rats exposed later
in development to d-MA also exhibited
heightened startle (Figure 10) and they
committed more errors in a complex water
maze (Figure 11) (26,27).
Note, however, that the effect on errors
of commission in the complex water maze
was relatively small and occurred only in
those rats exposed during the second ofthe
two exposure periods examined. More
striking than this is the effect MA exposure
had on the development oflearning in the
Morris hidden platform maze. As can be
seen in Figure 12, the later-exposed group
showed a significant delay both in initial
learning and in learning a new goal posi-
tion when the platform was shifted to
another location (26,27). This shows just
how sensitive the developing brain is as a
function ofthe stage ofontogeny when the
exposure occurs. It is clear that effects on
learning can be induced by one drug at one
stage ofbrain development, but at another
stage by a different drug (compare pheny-
toin vs MA)
Discussion
The developmental neurotoxicity of three
drugs has been reviewed in order to illus-
trate effects from both therapeutic and
illicit categories of drugs to which people
are exposed and which either induce or
show the potential for inducing learning
disabilities following in utero exposure. In
each case both human and experimental
animal data were presented and compared
where possible. The findings point to sev-
eral conclusions. First, drugs in some cur-
rent use appear to induce developmental
neurotoxicity; therefore, it is not correct to
assume that the current pharmacopoeia of
approved drugs is free of developmental
neurotoxins. Second, among the types of
neurotoxicity these drugs induce, learning
disabilities are prominent, sometimes the
most prominent, effect observed. Third,
the effects observed are dependent on both
the drug's mechanism of action and the
period during brain development when
exposure occurs. Fourth, it is evident that
simple predictions about critical periods
during brain development that are most
vulnerable for the induction of learning
disorders are not yet possible, as seen by
the different patterns ofcritical periods for
phenytoin and isotretinoin compared to
methamphetamine. Fifth, it is evident from
the example of isotretinoin, that we not
only face the problem of attempting to
identify and correct cases of drugs already
on the market that induce developmental
neurotoxicity, but our society continues to
introduce new developmental neurotoxins
that must be uncovered. In this regard, the
government's stated position that its cur-
rent testing is adequate is obviously incor-
rect, otherwise the isotretinoin case would
never have happened. Sixth, current
research expenditures only permit us to
assess a small percentage of the drugs cur-
rently in use and to detect only the most
serious types of developmental neurotoxic-
ity; we know almost nothing about this
aspect of toxicity for most drugs and we
know even less about more subtle types of
developmental neurotoxicity. This is a
source of concern, because we appear to
have only scratched the surface when it
comes to knowing all the types of CNS
damage prenatal drugs are capable of
inducing.
Nevertheless, one promising avenue is
now becoming feasible for dealing with
some ofthese drug-induced problems: pre-
vention. Most instances of developmental
neurotoxicity could be prevented with cur-
rent techniques of assessment if these were
incorporated in preclinical testing for all
drugs and other agents to which people are
exposed in significant quantities. The only
thing standing between us and this benefit
is the Federal government. The scientific
basis for regulatory action exists already.
Proof of this is to be found in regulatory
actions already taken by the US
Environmental Protection Agency. Other
agencies can follow suit anytime they
choose to do so.
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